Sign up to save your podcasts
Or
Share S2 Episode 4: Endometrial Cancer Trends: Immunotherapy Insights and Research Priorities
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
S2 Episode 4: Endometrial Cancer Trends: Immunotherapy Insights and Research Priorities
Drs Ursula A. Matulonis and Gini Fleming discuss the state of endometrial cancer, the role of immunotherapy, and priorities for research in this field.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001981. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Cancer Statistics, 2025 https://pubmed.ncbi.nlm.nih.gov/39817679/
Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype https://pubmed.ncbi.nlm.nih.gov/35511145/
The Advent of Immune Checkpoint Inhibition for the Treatment of Patients With Primary Advanced or Recurrent dMMR/MSI High Endometrial Cancer in 2025 https://pubmed.ncbi.nlm.nih.gov/39611619/
Overall Survival in Patients With Endometrial Cancer Treated With Dostarlimab Plus Carboplatin-Paclitaxel in the Randomized ENGOT-EN6/GOG-3031/RUBY Trial https://pubmed.ncbi.nlm.nih.gov/38866180/
Safety and Antitumor Activity of Dostarlimab in Patients With Advanced or Recurrent DNA Mismatch Repair Deficient/Microsatellite Instability-High (dMMR/MSI-H) or Proficient/Stable (MMRp/MSS) Endometrial Cancer: Interim Results From GARNET-A Phase I, Single-Arm Study https://pubmed.ncbi.nlm.nih.gov/35064011/
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (Phesgo) in Her2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma https://www.nrgoncology.org/Clinical-Trials/Protocol/nrg-gy026?filter=nrg-gy026
A New Vision for Women's Health Research: Transformative Change at the National Institutes of Health https://pubmed.ncbi.nlm.nih.gov/39652697/
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial https://pubmed.ncbi.nlm.nih.gov/37870536/
Antibody-Drug Conjugates as Targeted Therapy for Treating Gynecologic Cancers: Update 2025 https://pubmed.ncbi.nlm.nih.gov/39480912/
A Phase II Study of Frontline Paclitaxel/Carboplatin/Bevacizumab, Paclitaxel/Carboplatin/Temsirolimus, or Ixabepilone/Carboplatin/Bevacizumab in Advanced/Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/29804638/
View all episodes
By MedscapeDrs Ursula A. Matulonis and Gini Fleming discuss the state of endometrial cancer, the role of immunotherapy, and priorities for research in this field.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001981. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Cancer Statistics, 2025 https://pubmed.ncbi.nlm.nih.gov/39817679/
Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype https://pubmed.ncbi.nlm.nih.gov/35511145/
The Advent of Immune Checkpoint Inhibition for the Treatment of Patients With Primary Advanced or Recurrent dMMR/MSI High Endometrial Cancer in 2025 https://pubmed.ncbi.nlm.nih.gov/39611619/
Overall Survival in Patients With Endometrial Cancer Treated With Dostarlimab Plus Carboplatin-Paclitaxel in the Randomized ENGOT-EN6/GOG-3031/RUBY Trial https://pubmed.ncbi.nlm.nih.gov/38866180/
Safety and Antitumor Activity of Dostarlimab in Patients With Advanced or Recurrent DNA Mismatch Repair Deficient/Microsatellite Instability-High (dMMR/MSI-H) or Proficient/Stable (MMRp/MSS) Endometrial Cancer: Interim Results From GARNET-A Phase I, Single-Arm Study https://pubmed.ncbi.nlm.nih.gov/35064011/
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (Phesgo) in Her2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma https://www.nrgoncology.org/Clinical-Trials/Protocol/nrg-gy026?filter=nrg-gy026
A New Vision for Women's Health Research: Transformative Change at the National Institutes of Health https://pubmed.ncbi.nlm.nih.gov/39652697/
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial https://pubmed.ncbi.nlm.nih.gov/37870536/
Antibody-Drug Conjugates as Targeted Therapy for Treating Gynecologic Cancers: Update 2025 https://pubmed.ncbi.nlm.nih.gov/39480912/
A Phase II Study of Frontline Paclitaxel/Carboplatin/Bevacizumab, Paclitaxel/Carboplatin/Temsirolimus, or Ixabepilone/Carboplatin/Bevacizumab in Advanced/Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/29804638/